Advances in the use of nanocarriers for cancer diagnosis and treatment

被引:45
作者
Vieira, Debora Braga [1 ]
Gamarra, Lionel Fernel [1 ]
机构
[1] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil
来源
EINSTEIN-SAO PAULO | 2016年 / 14卷 / 01期
基金
巴西圣保罗研究基金会;
关键词
Nanomedicine; Liposomes; Nanoparticles; Neoplasms/drug therapy; Drug delivery systems;
D O I
10.1590/S1679-45082016RB3475
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The use of nanocarriers as drug delivery systems for therapeutic or imaging agents can improve the pharmacological properties of commonly used compounds in cancer diagnosis and treatment. Advances in the surface engineering of nanoparticles to accommodate targeting ligands turned nanocarriers attractive candidates for future work involving targeted drug delivery. Although not targeted, several nanocarriers have been approved for clinical use and they are currently used to treat and/or diagnosis various types of cancers. Furthermore, there are several formulations, which are now in various stages of clinical trials. This review examined some approved formulations and discussed the advantages of using nanocarriers in cancer therapy.
引用
收藏
页码:99 / 103
页数:5
相关论文
共 30 条
[1]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[2]  
Bross PF, 2001, CLIN CANCER RES, V7, P1490
[3]   Supramolecular nanoscale assemblies for cancer diagnosis and therapy [J].
Coelho, Silvia Castro ;
Pereira, Maria Carmo ;
Juzeniene, Asta ;
Juzenas, Petras ;
Coelho, Manuel A. N. .
JOURNAL OF CONTROLLED RELEASE, 2015, 213 :152-167
[4]   TISSUE DISTRIBUTION OF ANTI-TUMOR DRUGS ASSOCIATED WITH POLYALKYLCYANOACRYLATE NANOPARTICLES [J].
COUVREUR, P ;
KANTE, B ;
LENAERTS, V ;
SCAILTEUR, V ;
ROLAND, M ;
SPEISER, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (02) :199-202
[5]   TOXICITY OF POLYALKYLCYANOACRYLATE NANOPARTICLES .2. DOXORUBICIN-LOADED NANOPARTICLES [J].
COUVREUR, P ;
KANTE, B ;
GRISLAIN, L ;
ROLAND, M ;
SPEISER, P .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (07) :790-792
[6]   FDA drug approval summary:: Pegaspargase (Oncaspar ®) for the first-line treatment of children with acute lymphoblastic leukemia (ALL) [J].
Dinndorf, Patricia Anne ;
Gootenberg, Joseph ;
Cohen, Martin H. ;
Keegan, Patricia ;
Pazdur, Richard .
ONCOLOGIST, 2007, 12 (08) :991-998
[7]   Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics [J].
Dobrovolskaia, Marina A. ;
McNeil, Scott E. .
EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (07) :1163-1175
[8]   Polymer conjugates as anticancer nanomedicines [J].
Duncan, Ruth .
NATURE REVIEWS CANCER, 2006, 6 (09) :688-701
[9]  
Gabizon AA, 2001, CLIN CANCER RES, V7, P223
[10]   Nanotechnology: Future of Oncotherapy [J].
Gharpure, Kshipra M. ;
Wu, Sherry Y. ;
Li, Chun ;
Lopez-Berestein, Gabriel ;
Sood, Anil K. .
CLINICAL CANCER RESEARCH, 2015, 21 (14) :3121-3130